Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Non-Invasive Bladder Urothelial Carcinoma

Tundra lists 4 Non-Invasive Bladder Urothelial Carcinoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT04617743

The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-14

Bladder Cancer Recurrent
Non-Invasive Bladder Urothelial Carcinoma
RECRUITING

NCT05037279

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-20

3 states

Bladder Cancer
Bladder Cancer Recurrent
Neoplasm Recurrence
+3
ACTIVE NOT RECRUITING

NCT05768347

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

Gender: All

Ages: 18 Years - Any

Updated: 2025-12-04

1 state

Urothelial Carcinoma
Non-Invasive Bladder Urothelial Carcinoma
NOT YET RECRUITING

NCT05335512

Intravesical BCG: is the Urinary Bladder Ready to Receive it

Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT. and also to validate a grading system of healing of the bladder mucosa after TURBT. To assess the factors influencing bladder healing is also one of the secondary objectives.

Gender: All

Updated: 2022-06-09

Non-Invasive Bladder Urothelial Carcinoma